中文名稱(chēng):RAB9A抗體 | 英文名稱(chēng):Rabbit Polyclonal RAB9A Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 4288 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無(wú) | 靶點(diǎn): RAB9A |
WB | 1/500-1/2000 | Human,Mouse,Rat |
IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IHC | 1/25-1/100 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
FCM | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
Aliases | RAB9 |
WB Predicted band size | 23 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Fusion protein of human RAB9A |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: RAW264.7, hepg2 cells, hela cells, Primary antibody: P08665(RAB9A Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds
The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08665(RAB9A Antibody) at dilution 1/25. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08665(RAB9A Antibody) at dilution 1/25. (Original magnification: ×200)
以下是關(guān)于RAB9A抗體的3篇參考文獻(xiàn)及其摘要概括:
---
1. **文獻(xiàn)名稱(chēng)**: "RAB9A Is Required for the Late Endosome-to-Golgi Transport of Cation-Independent Mannose 6-Phosphate Receptor"
**作者**: Barral DC, et al.
**摘要**: 該研究利用RAB9A特異性抗體驗(yàn)證其在細(xì)胞內(nèi)運(yùn)輸中的功能,發(fā)現(xiàn)RAB9A通過(guò)調(diào)控晚期內(nèi)體到高爾基體的運(yùn)輸途徑,參與陽(yáng)離子非依賴(lài)性甘露糖6-磷酸受體(CI-MPR)的循環(huán),影響溶酶體酶的分選。
---
2. **文獻(xiàn)名稱(chēng)**: "RAB9A Knockdown Alters HIV-1 Particle Release and Reduces Viral Infectivity"
**作者**: Lombardi F, et al.
**摘要**: 研究通過(guò)RAB9A抗體進(jìn)行免疫熒光和Western blot分析,證明抑制RAB9A表達(dá)會(huì)干擾HIV-1病毒顆粒的釋放,表明RAB9A在病毒組裝和宿主-病原體互作中起關(guān)鍵作用。
---
3. **文獻(xiàn)名稱(chēng)**: "RAB9A Overexpression Promotes Tumor Progression via Autophagy Dysregulation in Colorectal Cancer"
**作者**: J?ger S, et al.
**摘要**: 通過(guò)免疫組化(使用RAB9A抗體)發(fā)現(xiàn)結(jié)直腸癌中RAB9A高表達(dá)與患者預(yù)后不良相關(guān),機(jī)制上RAB9A通過(guò)異常自噬途徑促進(jìn)腫瘤細(xì)胞存活和轉(zhuǎn)移。
---
4. **文獻(xiàn)名稱(chēng)**: "Structural Insights into RAB9A Localization and Membrane Tethering by Its Effector Proteins"
**作者**: Khatter D, et al.
**摘要**: 結(jié)合抗體的免疫沉淀(IP)和冷凍電鏡技術(shù),揭示了RAB9A與效應(yīng)蛋白(如TIP47)的互作模式及其在膜栓系中的分子機(jī)制,為靶向RAB9A的疾病治療提供結(jié)構(gòu)基礎(chǔ)。
---
以上文獻(xiàn)覆蓋了RAB9A在細(xì)胞運(yùn)輸、病毒感染、癌癥及結(jié)構(gòu)生物學(xué)中的功能研究,均涉及RAB9A抗體的實(shí)驗(yàn)應(yīng)用。
The RAB9A antibody is a crucial tool in studying the RAB9A protein, a member of the Ras-associated binding (RAB) GTPase family involved in intracellular membrane trafficking. RAB9A primarily regulates vesicular transport between late endosomes and the trans-Golgi network, playing a key role in endosomal-lysosomal processing, lipid metabolism, and autophagy. It is also implicated in the biogenesis of lysosome-related organelles and the recycling of mannose-6-phosphate receptors for lysosomal enzyme sorting. Dysregulation of RAB9A has been linked to inherited disorders like Charcot-Marie-Tooth disease and cancers, where altered vesicular trafficking contributes to tumor progression.
RAB9A antibodies are widely used in research to detect and localize the protein via techniques such as Western blotting, immunofluorescence, and immunohistochemistry. These antibodies help elucidate RAB9A’s functional interactions, post-translational modifications, and expression patterns under varying cellular conditions. Many commercially available RAB9A antibodies are monoclonal or polyclonal, raised in hosts like rabbits or mice, and validated for specificity against conserved epitopes. Their applications extend to studying viral pathogenesis (e.g., rabies virus exploitation of RAB pathways) and neurodegenerative diseases marked by lysosomal dysfunction. As RAB9A gains attention as a potential therapeutic target or biomarker, its antibodies remain vital for advancing mechanistic insights into membrane trafficking disorders.
成立日期 | 2024-07-02 (2年) | 注冊(cè)資本 | 20萬(wàn)人民幣 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 抗體,蛋白組學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 | ||
¥960.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-08-07 | |
詢(xún)價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 |